News about Clinical Trials

Lundbeck to Present Movement Disorder Data at MDS 2026

Lundbeck presents new movement disorder research covering MSA clinical development and advanced Parkinson’s disease.

Clinical Trials | 05/10/2026 | By News Bureau

Litfulo Shows Significant Repigmentation Benefits in Phase 3

Pfizer’s two phase 3 trials showed significant improvements in facial and total body repigmentation compared with placebo.

Clinical Trials | 05/10/2026 | By News Bureau

Teva Reports Ecopipam Data in Pediatric Tourette Syndrome

Teva Pharmaceuticals has reported new ecopipam data showing clinically meaningful tic reduction in about 70 percent of pediatric Tourette Syndrome patients within 8 weeks.

Clinical Trials | 05/10/2026 | By News Bureau

Sun Pharma Presents Long-Term Leqselvi Data

Sun Pharma presents long-term safety and efficacy data for Leqselvi in adults with severe alopecia areata at the EADV Congress 2026.

Clinical Trials | 03/10/2026 | By News Bureau

Roche Reports New Real-World Vabysmo Data Across Retinal Conditions

Roche’s VOYAGER study provides real-world data on Vabysmo’s effectiveness, durability and safety across multiple retinal conditions.

Clinical Trials | 03/10/2026 | By News Bureau

Pierre Fabre Resubmits Tabelecleucel BLA to FDA

Pierre Fabre Pharmaceuticals resubmits tabelecleucel BLA for treatment of Epstein-Barr virus positive -post-transplant lymphoproliferative disease to the FDA.

Clinical Trials | 03/10/2026 | By News Bureau

Merck Reports Positive Phase 2b Tulisokibart Results in Hidradenitis Suppurativa

Merck reported Phase 2b results for investigational tulisokibart in patients with moderate to severe hidradenitis suppurativa.

Clinical Trials | 01/10/2026 | By News Bureau

Acurx Enrolls First Patient in PATHFINDER C. difficile Trial

Acurx Pharmaceuticals has announced the first patient enrolled in PATHFINDER clinical trial of ibezapolstat in multiply-recurrent C. difficile infection.

Clinical Trials | 01/10/2026 | By News Bureau

Lilly's Zepbound Shows More Weight Loss Than Wegovy HD in Analysis

Lilly’s Zepbound (tirzepatide 10 mg and 15 mg) was associated with greater weight loss than Wegovy HD (semaglutide 7.2 mg) in an indirect comparison.

Clinical Trials | 01/10/2026 | By News Bureau

Silexion Reports Positive Findings for RNAi Candidate SIL204

Silexion Therapeutics reports new findings supporting the cellular uptake and gene-silencing mechanism of its investigational RNAi candidate SIL204.

Clinical Trials | 30/09/2026 | By News Bureau